ASX - By Stock
|
AVR |
Re:
Investor call being scheduled
|
|
barracudaking
|
61 |
32K |
4 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
61
|
32K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
8 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
289
|
133K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Credit Suisse report on Admedus
|
|
barracudaking
|
8 |
7.9K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
8
|
7.9K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Credit Suisse report on Admedus
|
|
barracudaking
|
8 |
7.9K |
6 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
8
|
7.9K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Credit Suisse report on Admedus
|
|
barracudaking
|
8 |
7.9K |
2 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
8
|
7.9K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Appendix 4C - quarterly
|
|
barracudaking
|
43 |
18K |
8 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
43
|
18K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Appendix 4C - quarterly
|
|
barracudaking
|
43 |
18K |
0 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
43
|
18K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Appendix 4C - quarterly
|
|
barracudaking
|
43 |
18K |
11 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
43
|
18K
|
11
|
|
ASX - By Stock
|
AVR |
Re:
Proposal to be considered at EGM
|
|
barracudaking
|
122 |
66K |
5 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
122
|
66K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
barracudaking
|
111 |
71K |
7 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
111
|
71K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
barracudaking
|
111 |
71K |
2 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
111
|
71K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
barracudaking
|
111 |
71K |
1 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
111
|
71K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Proposal to be considered at EGM
|
|
barracudaking
|
122 |
66K |
6 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
122
|
66K
|
6
|
|
ASX - By Stock
|
SP1 |
Re:
Ann: Letter to Shareholders
|
|
barracudaking
|
100 |
54K |
6 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
100
|
54K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: SAVR Clinical Trial
|
|
barracudaking
|
72 |
39K |
11 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
72
|
39K
|
11
|
|
ASX - By Stock
|
AVR |
Wayne interview with The Australian Business Executive
|
|
barracudaking
|
0 |
1.0K |
16 |
21/01/20 |
21/01/20 |
ASX - By Stock
|
0
|
1.0K
|
16
|
|
ASX - By Stock
|
AVR |
Re:
TAVR presented at #JPM2020 by CEO
|
|
barracudaking
|
40 |
19K |
5 |
21/01/20 |
21/01/20 |
ASX - By Stock
|
40
|
19K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
TAVR presented at #JPM2020 by CEO
|
|
barracudaking
|
40 |
19K |
6 |
16/01/20 |
16/01/20 |
ASX - By Stock
|
40
|
19K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
TAVR presented at #JPM2020 by CEO
|
|
barracudaking
|
40 |
19K |
4 |
16/01/20 |
16/01/20 |
ASX - By Stock
|
40
|
19K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Opportunity in TMVR
|
|
barracudaking
|
18 |
15K |
10 |
13/01/20 |
13/01/20 |
ASX - By Stock
|
18
|
15K
|
10
|
|
ASX - By Stock
|
AVR |
Re:
Opportunity in TMVR
|
|
barracudaking
|
18 |
15K |
9 |
12/01/20 |
12/01/20 |
ASX - By Stock
|
18
|
15K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Update to LeMaitre Vascular deal
|
|
barracudaking
|
86 |
66K |
2 |
10/12/19 |
10/12/19 |
ASX - By Stock
|
86
|
66K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Update to LeMaitre Vascular deal
|
|
barracudaking
|
86 |
66K |
11 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
86
|
66K
|
11
|
|
ASX - By Stock
|
AVR |
Leading Global TAVR Expert Says ADAPT is a GAME CHANGER!
|
|
barracudaking
|
43 |
25K |
31 |
28/11/19 |
28/11/19 |
ASX - By Stock
|
43
|
25K
|
31
|
|
ASX - By Stock
|
TD1 |
Re:
Ann: Trading Halt
|
|
barracudaking
|
406 |
286K |
2 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
406
|
286K
|
2
|
|
ASX - By Stock
|
TD1 |
Re:
Ann: Trading Halt
|
|
barracudaking
|
406 |
286K |
0 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
406
|
286K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Proactive interview with Wayne Paterson
|
|
barracudaking
|
35 |
18K |
23 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
35
|
18K
|
23
|
|
ASX - By Stock
|
AVR |
Re:
TAVR/TMVR market projected to reach $8B by 2023
|
|
barracudaking
|
34 |
21K |
5 |
14/11/19 |
14/11/19 |
ASX - By Stock
|
34
|
21K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Appendix 4C - quarterly
|
|
barracudaking
|
152 |
87K |
12 |
02/11/19 |
02/11/19 |
ASX - By Stock
|
152
|
87K
|
12
|
|
ASX - By Stock
|
AVR |
Re:
Why Admedus’ shift to aortic valve replacement is good news for patients under 65
|
|
barracudaking
|
42 |
21K |
11 |
29/10/19 |
29/10/19 |
ASX - By Stock
|
42
|
21K
|
11
|
|
ASX - By Stock
|
AVR |
Re:
Why Admedus’ shift to aortic valve replacement is good news for patients under 65
|
|
barracudaking
|
42 |
21K |
9 |
26/10/19 |
26/10/19 |
ASX - By Stock
|
42
|
21K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
Why Admedus’ shift to aortic valve replacement is good news for patients under 65
|
|
barracudaking
|
42 |
21K |
4 |
26/10/19 |
26/10/19 |
ASX - By Stock
|
42
|
21K
|
4
|
|
ASX - By Stock
|
AVR |
Why Admedus’ shift to aortic valve replacement is good news for patients under 65
|
|
barracudaking
|
42 |
21K |
20 |
25/10/19 |
25/10/19 |
ASX - By Stock
|
42
|
21K
|
20
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
6 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
289
|
133K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
10 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
289
|
133K
|
10
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
4 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
289
|
133K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
1 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
289
|
133K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Munich stuff
|
|
barracudaking
|
25 |
14K |
6 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
25
|
14K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
5 |
14/10/19 |
14/10/19 |
ASX - By Stock
|
289
|
133K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
|
|
barracudaking
|
289 |
133K |
19 |
14/10/19 |
14/10/19 |
ASX - By Stock
|
289
|
133K
|
19
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
0 |
04/07/19 |
04/07/19 |
ASX - By Stock
|
314
|
125K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
0 |
01/07/19 |
01/07/19 |
ASX - By Stock
|
314
|
125K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
1 |
27/06/19 |
27/06/19 |
ASX - By Stock
|
314
|
125K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: POSITIVE DATA ON CARDIOCEL PUBLISHED IN LEADING JOURNAL
|
|
barracudaking
|
10 |
5.2K |
2 |
24/06/19 |
24/06/19 |
ASX - By Stock
|
10
|
5.2K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
New Report
|
|
barracudaking
|
21 |
12K |
0 |
20/06/19 |
20/06/19 |
ASX - By Stock
|
21
|
12K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
New Report
|
|
barracudaking
|
21 |
12K |
2 |
20/06/19 |
20/06/19 |
ASX - By Stock
|
21
|
12K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
New Report
|
|
barracudaking
|
21 |
12K |
3 |
20/06/19 |
20/06/19 |
ASX - By Stock
|
21
|
12K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
0 |
17/06/19 |
17/06/19 |
ASX - By Stock
|
314
|
125K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
0 |
16/06/19 |
16/06/19 |
ASX - By Stock
|
314
|
125K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Extension for Voluntary Suspension
|
|
barracudaking
|
314 |
125K |
8 |
15/06/19 |
15/06/19 |
ASX - By Stock
|
314
|
125K
|
8
|
|